DoctorLila Landowski

Senior Lecturer in Biomedical Sciences

Health Sciences

RESEARCH SUMMARy

Expertise
Stroke
Nerve regeneration
Axon guidance
Peripheral Neuropathy
Chemotherapy-induced Neuropathy
Diabetic Neuropathy
Neurodevelopment

Stress and burnout

Technology overuse impacts on the brain
Histology (microanatomy)

Research Biography:
As a neuroscientist, Lila’s research expertise spans across axon guidance, therapeutic development for nerve injury, stroke and fatigue. In 2014, after completing her PhD at the Menzies Research Institute Tasmania, Lila trained at the Peripheral Nerve lab at the Mayo Clinic to cement her status as an emerging leader in the field of peripheral nerve injury. She was recruited to teach and coordinate neuroscience units at the Wicking Dementia Centre at the same time. In recent years, her research focus has shifted from peripheral neuropathy to stroke. She is currently a postdoctoral fellow in the lab of Professor David Howells. For several months across late 2016-early 2017, Lila spent time as a visiting scholar at the Florey Institute’s Melbourne Brain Centre (Austin Hospital, Melbourne), developing surgical skills research to bring back to UTAS. With the support of a $450,000 investment from the Royal Hobart Hospital Research Foundation, her foremost research goal is to transform the success of preclinical stroke research. Through improving preclinical models of stroke, we may save as much as $1.9bn in the $14.9bn research cost of developing new stroke therapies.

Research Themes
Lila’s research aligns to the theme of Better Health.
Her current research portfolio has two major projects (stroke and fatigue)

Stroke - The cost of stroke in the developed world is up to an estimated A$1475 billion a year. Despite decades of research, drug development for stroke has failed repeatedly. Of the 1000+ promising therapeutics developed for stroke in animal models, only one is used clinically. Even then, the utility and applicability of this drug is limited. Research from our laboratory suggests that the primary reason for the failure of translation arises from flaws with the stroke models themselves. However, we have devised a clever solution to overcome these limitations; my role is to establish this new gold-standard model of stroke. These improvements are critical: they will increase the face validity of stroke modelling, allow us to test hypotheses critical to our understanding of stroke biology and improve the success of preclinical translational stroke research. We estimate that even modest improvements in stroke modelling might achieve savings of ~$1.9bn in the estimated $14.6bn research cost of developing a new stroke therapy.

Fatigue - Fatigue is much more than just a sense of tiredness. It is also a debilitating symptom of many diseases and disorders, hampering peoples’ ability to perform the simplest of daily activities. The underlying mechanism of fatigue is unknown. We hypothesise that fatigue is ultimately a disorder resulting from an energy deficit in the brain.

Neonatal versus adult nerve regeneration – Neonate and young children's brains have a remarkable ability to recover from neuronal injury. Understanding this process will have very important implications for improving recovery from neurological diseases and injury in adults.

Neuropathy - Development of a therapeutic for chemotherapy induced neuropathy. Imagine surviving cancer, only to suffer from debilitating pain for the rest of your life? Unfortunately, this is a common reality for many people who have had chemotherapy for cancer. We have developed compelling evidence that the protein metallothionein can accelerate regeneration of peripheral nerves. Lila would like to identify whether metallothionein can be used as prophylactic agent to prevent or reduce chemotherapy-induced neuropathy.


FUNDED PROJECTS

  • GRANT
    A new theory of fatigue: The role of AgRP neurons in ME/CFS
    1 Jan 2021 - 31 Dec 2024
    People funded by this grant:
    • Sutherland B,
    • Herzog H,
    • Landowski L
    Project Total: $268,200; Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex multi-system disease for which there is no cure. It is often characterised by fatigue, post-exertional malaise, cognitive dysfunction, muscle weakness, slowed reflexes and coordination, sleep disturbances, fever, myalgia, photosensitivity and neuro-immuno-endocrine dysfunction1 which can be disabling and dramatically impact quality of life. Some 190-240,000 Australians have been diagnosed with ME/CFS with many more probably undiagnosed. The fatigue experienced by patients with ME/CFS shares many features with the fatigue experienced in other conditions ranging from severe infections through cancer and brain injury to autoimmune diseases. Often the fatigue is overlooked by the medical profession and researchers alike. Never-the-less it is estimated that 38% of adults are affected by fatigue at some stage. Importantly for many, like patients with ME/CFS, there is no identifiable underlying pathology to blame and when there is a known pathology, the fatigue does not usually resolve with treatment of that pathology. We believe that fatigue is caused by an independent pathological process that can be triggered by many disease stimuli and can perpetuate independently of an associated trigger. We propose an overarching mechanism for all-cause fatigue driven by protective energy homeostasis mechanisms driven by neurons in the arcuate nucleus of the hypothalamus. These Agouti-related protein (AgRP) expressing neurons, occupy an unusual niche in the brain. They are well known for their role in regulating energy balance, but they also interact with the stress, anxiety, circadian and inflammation regulatory pathways of the hypothalamic-pituitary axis which are already known for participation in the pathology of fatigue. Importantly they are not protected by a structure called the blood-brain-barrier so are readily damaged by circulating inflammatory and stress stimuli. Moreover, they can be killed by such stimuli but also have the capacity to be replenished over time. These features make them good candidates to underpin the pathology of fatigue. We hypothesise that ME/CFS manifests when AgRP neuron signalling is impaired, resulting in a loss of homeostatic drive to promote arousal, attention and activity. We further hypothesise that restoration or replacement of AgRP neuron signalling will treat ME/CFS. We will test these hypotheses using transgenic mice developed by our multidisciplinary team that allow us to genetically control the activity of AgRP neurons and the regulation of the blood-brain-barrier and determine how they respond to inflammatory stimuli commonly used to generate animal models of ME/CFS-related fatigue. By examining how these animals then respond to drugs that change either the activity or the number of AgRP neurons, we will be able to determine whether this mechanism can be targeted to treat fatigue. If successful, these later proof-of-principle interventions may provide translatable therapies in their own right but are expected to pave the way for more refined medicinal chemistry. While the primary target of this research is finding a therapy that benefits patients with ME/CFS, our hypothesis is applicable to all forms of fatigue, whether associated with cancer, brain injury, autoimmune disease or severe infection. Importantly, while repopulation of lost AgRP neurons will take time, pharmacological mimicking of their function should produce immedi Funded by: Equity Trustees Limited - Grant-Mason Foundation ME/CFS ($268,200); University of Tasmania.
  • GRANT
    Blood-brain barrier energy dysfunction: the unifying cause of fatigue
    1 Jan 2017 - 30 Jun 2018
    People funded by this grant:
    • Howells D,
    • Sutherland B,
    • Landowski L,
    • Eaton E,
    • Allan
    Project Total: $99,874; Fatigue can be much more than just a sense of tiredness. It is also a debilitating symptom of many diseases and disorders, hampering peoples' ability to perform the simplest of daily activities. The underlying mechanism of fatigue is unknown. We hypothesise that fatigue is ultimately the result of reduced delivery of energy to the brain. We will assess how energy supply is altered in fatigued brain. A special diet (that supplies an alternative energy source for the brain) will be used to circumvent this energy deficit. We hope to establish how fatigue occurs and offer clues to a simple treatment strategy. Funded by: The Mason Foundation - Grant-Judith Jane Mason & Harold Stannett Williams ($99,874); University of Tasmania.
  • GRANT
    Paving the way for future stroke drug development: creating a new gold-standard model of stroke
    1 Jan 2017 - 31 Mar 2021
    People funded by this grant:
    • Landowski L,
    • Howells D,
    • Castley H,
    • Sutherland B,
    • Kirkcaldie M
    Project Total: $442,570; Stroke is a leading cause of death and chronic disability. Stroke therapeutics developed in animal models fail when translated into human clinical trials, due to flaws inherent in these models. We will break through this translational roadblock by using magnetic microparticles to induce an ischemic stroke that accurately represents human disease Funded by: Royal Hobart Hospital Research Foundation - Grant - Project Grant Funding ($442,570); University of Tasmania.
  • GRANT
    Development of a therapeutic agent for a chemotherapy-induced neuropathy
    1 Mar 2015 - 31 Jul 2016
    People funded by this grant:
    • Taylor B,
    • Landowski L,
    • West A,
    • Vickers J,
    • Foa L
    Project Total: $21,739; Chemotherapy-induced neuropathy (CIN) is a dose-limiting side effect of chemotherapy treatment, causing irreversible disability in 40% of cancer survivors. CIN results from the loss or damage of neurons during chemotherapy. We have compelling evidence that the protein metallothionein promotes regeneration of peripheral nerves, and examine its therapeutic use in CIN. This project will create new knowledge in the area of chemotherapy induced neuropathy, and establish the suitability of trophic agents as disease-modifying agents for chemotherapy-induced neuropathy. Funded by: Royal Hobart Hospital Research Foundation - Grant-Clinical Research ($21,739); University of Tasmania.